Methods and kits for sampling mucous from within a sinus to determine if a single sample includes one or more bacterial types indicating a bacterial infection, such as bacterial sinusitis, and one or more viruses indicating a viral infection, such as influenza.

A fusion protein including a phage tail-spike protein ΦAB6TSP and a signal indicator is provided. Also, a method of detecting bacteria having pseudaminic acid (Pse) is provided, including steps of contacting a sample with a phage tail-spike protein ΦDAB6TSP; and detecting a signal from the sample. The fusion protein and the method of detecting bacteria can be applied to a set of practical diagnosis and therapeutic alternative against Pse-coated antibiotic resistant pathogenic bacteria.

Described are a therapeutic monoclonal antibody specific for the Type Six Secretion System (T6SS) needle protein of Acinetobacter baumannii (A. baumannii) and methods of use. Specifically, the antibody specifically binds to hemolysin co-regulated protein (Hep). Further disclosed are methods of using an anti-Hep antibody for detecting A. baumannii in a sample as well as a mutant A. baumannii strain comprising a deletion or mutation in its genome such that said deletion or mutation interrupts the proper translation of its hep protein.

The present invention relates to in vitro assays, more particularly ELISA assays. Said ELISA assays comprise antibodies capable of binding Ubiquitous surface protein A2 (UspA2) from Moraxella catarrhalis. The present invention relates to assays for assessing the binding of antibodies to UspA2 and the relative potency of vaccine test samples comprising UspA2. In particular, the invention relates to in vitro relative potency assays used in the release of vaccine that comprises UspA2 to the public.

The present invention provides means and products for the stimulation of an immune response against tumors in a subject in need thereof. More specifically the invention provides immunogenic compositions containing bacterial outer membrane vesicles loaded with tumor antigens, fusion proteins comprising a bacterial protein and a tumor antigen, and isolated bacterial outer membrane vesicles (OMVs) containing said fusion proteins. The fusion proteins, OMVs and immunogenic compositions according to the invention are used in the prevention and treatment of tumors.

Apparatuses for sampling mucous from within a sinus to determine if a single sample includes one or more bacterial types indicating bacterial sinusitis comprising an indicator to guide the angle at which a user inserts the apparatus relative to the patient.

Described are a therapeutic monoclonal antibody specific for the Type Six Secretion System (T6SS) needle protein of Acinetobacter baumannii (A. baumannii) and methods of use. Specifically, the antibody specifically binds to hemolysin co-regulated protein (Hep). Further disclosed are methods of using an anti-Hep antibody for detecting A. baumannii in a sample as well as a mutant A. baumannii strain comprising a deletion or mutation in its genome such that said deletion or mutation interrupts the proper translation of its hep protein.

The invention relates to a method for identification and discrimination of bacteria and/or mutant bacterial strains in a biological fluid. The method includes illuminating the biological fluid with a beam of light; obtaining Raman data from light scattered from the illuminated biological fluid; and finding Raman signatures corresponding to each type of bacteria and/or mutant bacterial strains from the obtained Raman data, so as to identify and discriminate each type of bacteria and/or mutant bacterial strains in the biological fluid from the Raman signatures.

Apparatuses for sampling mucous from within a sinus to determine if a single sample includes one or more bacterial types indicating bacterial sinusitis comprising an indicator to guide the angle at which a user inserts the apparatus relative to the patient.

In this application is described a mutant Acinobacter baumannii strain having a deletion or mutation in its genome. The deletion or mutation interrupts the proper translation of the Hcp protein.